Cytomegalovirus retinitis after subtenon triamcinolone acetonide and intravitreal injection of anti-vascular endothelial growth factor in an immunocompetent patient with age-related macular degeneration and diabetes mellitus.
Toyokawa
Noriko
N
Kimura
Hideya
H
Kuroda
Shinichiro
S
D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D017726:Cytomegalovirus Retinitis / Q000175:diagnosis / Q000209:etiology* / Q000601:surgery; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004359:Drug Therapy, Combination; D005205:Fascia; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D016867:Immunocompromised Host; D007267:Injections / Q000009:adverse effects*; D008268:Macular Degeneration / Q000150:complications*; D008297:Male; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014821:Vitrectomy; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide
Arch Ophthalmol. 2005 Apr;123(4):572-4
15824240
Acta Ophthalmol Scand. 2007 Sep;85(6):681-3
17403022
Am J Ophthalmol. 2005 Dec;140(6):1141-3
16376669
Invest Ophthalmol Vis Sci. 1998 Oct;39(11):2190-4
9761301
Nippon Ganka Gakkai Zasshi. 2008 Aug;112(8):684-7
18767494